Zadzwoń do nas: 16 677 00 79, 16 671 87 77

ul. św Jana 32, Przemyśl Mapa

Paź 29

COVID-19 can be treated in 48 hours

COVID-19 can be treated in 48 hours

Dear readers.

My name is Włodzimierz Bodnar. I am a paediatrician and also a specialist in lung diseases, who has been treating patients continuously for over 30 years. I am writing as a practitioner, but also a person from the risk group (age and profession) that is himself a post-covid patient. With your help, I would like to implement/publish a treatment on how to overcome a severe case of disease caused by SARS-CoV-2. This is my appeal to the people of science and medicine of the world.


Being unheard

Let me explain first why I decided to publish this article. In the period between March and October 2020, I have documented over 100 COVID-19 cured cases – most of them quite acute – and more than a dozen more come every day. Some of these patients had comorbidities that increase the risk of serious health hazard and death.

Currently, I am convalescing myself after surviving a severe COVID-19 attack (confirmed by RT-PCR test). I am 59 years old and belong to a high-risk group for cardiac reasons. By using the method described below, my symptoms began to retreat 48 hours after starting treatment.

Now, I feel well enough, wholly cured and able to write this message myself, as well as treat patients continuously over the phone and in my clinic, in person. Each of my patients going through an acute phase of the infection keeps in touch and informs me about their health daily for the period of 3-4 days. 

In the last couple of months, most of my attempts at communicating this successful and innovative method of treatment failed. The institutions I have contacted included:

  • March 2020 Polish Ministry of Health – no answer
  • March 2020 Professor Katherine Kędzierski, chairman of Australian scientists (The Peter Doherty Institute for Infection and Immunity) – no answer
  • April 2020 Professor Krzysztof Simon, Department of Infectious Diseases Wrocław – no answer
  • In the meantime, multiple repeated attempts to reach the government and its representatives were unsuccessful
  • In July 2020, I published a description of my cases of treating patients which was sent to doctors all over Poland (Porozumienie Zielonogórskie) – unfortunately without much response
  • Also in July 2020, I received the only ever answer – a positive response came from Szczecin from Professor Cezary Pakulski, Department of Intensive Care Anaesthesiology and Emergency Medicine, who fully supported my observations. It restored my faith and strength to continue healing and writing about it
  • October 2020, Before getting sick, I published an article about how to treat COVID-19 in the local press – no significant response, even before my disease and recent treatment adjustments
  • I have been sending this message everywhere possible for the past ten days, without any answer received from neither the government nor the media

I strongly believe that with this method of treatment, at least 90% of severe, currently hospitalized, cases in Poland (or even worldwide) can be stabilized within 48 hours followed by a recovery period of several more days. 

Thanks to its wide availability and the usage of a well-tested drug, it will stop the disease before it does significant damage. It would also considerably change the way we are fighting the pandemic right now. Having an effective, safe drug changes everything.

The hypothesis

If we assume that we are looking for an antiviral drug that works directly against the virus, then, in this case, amantadine is entirely useless. If we believe that amantadine or some other medication will significantly alter the conditions of viral growth, an investigation is further needed. Viruses must have a well-defined host in which they ‘multiply’. I want to emphasize that a virus can only grow under the right conditions.

There has been research on how amantide works in general, and also how it can potentially work in case of SARS-CoV-2 infection (1). Still, for a practitioner, the most important thing is having a drug that changes the conditions of a virus’s development in a human cell and makes it unable to spread. This way, we can save health and life if the patient is still alive. 

After reaching the appropriate concentration of the drug – we act on the virus, deactivating it at every stage of the disease. In other words, in each case, we work on the cause of the disease, i.e. the virus, by eliminating it from the body (deactivation), be it the initial period of headaches or the late stage of pneumonia. It does not matter whether the patient is 30 or 100 years old, has comorbidities or not. The principle of the approach is the same, and it is to deactivate the virus. 

Deduction process and recommended scheme

To be more specific, my experiences and further research have focused only on Amantadine hydrochloride (Amantadini hydrochloridum), which – for reading purposes – I keep naming “amantadine”, which may or may not be an essential aspect of the treatment. Further research is required. 

Focusing on practice now: my observations from the 30-year period of treating viral diseases were helpful and, unfortunately, the last 60 days of the dynamically growing number of COVID-19 cases in Poland ‘helped me’ even more to gather data. 

I have come across a lot of very acute cases started by SARS-CoV-2. COVID-19 infections are much more severe than influenza that is easier to treat. Why? Because the dynamics of the latter disease is much slower. For example, if we look at the patient’s weight loss, COVID-19 patients lose about one kilogram of weight a day (most often lying in bed, doing nothing and drinking even more fluids than usual). From the perspective of a practitioning doctor, this proves that the disease is very dynamic. 

Initial treatment attempts, as in the case of influenza, may be insufficient because the symptoms of COVID-19 last much longer, i.e. 4 to 9 days. 

Singular studies about the potential positive influence of amantadine on COVID-19 have been conducted, but without any spectacular results (2). The reason here may be an insufficient dose of the drug fortherapeutic purposes. I started treatment with a different dose of amantadine. In this way, in most cases, there was a dramatic improvement after one day. Stabilization took place after two days, without major disease symptoms except for the sometimes slightly tiring cough. Thus, I came to premature conclusions that complete virus inactivation takes place in 72 hours, which does not have to be true. I emphasize that this is only my assumption, science will speak for itself in the future.

However, knowing the dynamics of the virus, it is safer to maintain prophylactic treatment until the body is sufficiently immune if there was a relapse of the disease. In a small percentage, amantadine can cause early arrhythmogenic symptoms. In the event of the occurrence of side effects, discontinue treatment completely no matter the stage of treatment. That is why constant everyday contact with a doctor is a key during this treatment.

When the disease is enormously progressing

When the patient’s medical history shows that the progress of the disease is very dynamic and acute (symptoms begin to increase hour by hour), we may suspect that in extreme cases the patient may be at risk of dying within a few hours. Seeing the effects of the therapy, I decided to race against time and introduce one more change to the treatment to shorten the time to reach the saturated therapeutic level as much as possible. 

In this model, I already have a lot of feedback where patients literally ‘get on their feet’ in a short time.

Why rapid treatment is important and additional recommendations

With quick treatment, we can avoid disability or irreversible changes in the body, complications or long-term treatment of other diseases e.g. pneumonia.

In addition to taking amantadine, the recommendation is a symptomatic treatment for e.g. fever. As in any disease, it is up to the doctor to decide on the antibiotic, if the virus has damaged internal organs, or during the regeneration and treatment of the consequences of COVID-19. Time is of the essence because the virus causes great damage to the body. Please keep in mind that the recovery process can depend on how late treatment with this regimen is started.

Here, I would also like to comment that postmortem publications describing clotting syndromes in patients may not be valid. These changes can be caused by a very severe cough, where the blood vessels in the chest burst. The patient’s breathing reflex is turned off, and they experience difficulty speaking (speech is effort), pain is stronger than breathing reflex.

The summary

The main drug (active substance) AMANTADINE, I am considering, is not included in the COVID-19 treatment regimens for now, although it is a drug known for about 30-40 years and used to treat other diseases. It is well-tested, known worldwide. With the use of it, we are already talking about causal treatment – that is, complete inactivation of the virus. It no longer works on the body, which is why the effect is so much improved. 

Once a virus has been deactivated, it will never attempt to replicate again. It takes at least 24 hours for the drug to enter the body in sufficient quantity and to change the environment for the virus. 

I expect that this drug will be immediately implemented in COVID-19 treatment scheme and may revolutionize the fight with pandemic worldwide, saving the health and life of millions.

Why am I doing this?

Seeing the effects both on the patients, who physically visit my clinic in a dozen or so a day, and telephone cases from all over Poland asking for help in saving lives, I cannot be indifferent to the situation. Only in the Podkarpackie Province, the number of positive results of SARS-CoV-2 tests ranges from 30% to even 93% (3), which may indicate a much broader scale of infections than we assume.

Knowing about the adequate daily dosage (48-72hours) and feedback on the effects, I decided in the favour of this publication to clearly show that I was able to stabilize over 90% of severe cases within 48 hours. Later, it is ‘just’ the treatment necessary after the damage already made by the virus. 

I do not plan to shy away from responsibility. This article is signed with my name, mentioning my specialization, and making me available for contact from both doctors and the media.

I live in suspense with the full awareness that people are dying. From my perspective, I have the feeling that the vast majority of them can potentially be cured, but there is nothing more I can do. Attempts at a scientific approach or media contact have not been successful for months. Therefore, I decided to act differently and present my conclusions in the form of an appeal of a practitioner to the general public with a request to spread this information as a bottom-up initiative.

After a few days, we have more and more publicity, also among doctors, but there is still dead silence in the main media channels. I know it has to change sometime soon. I want to thank all the people for their active participation in my appeal.

Włodzimierz Bodnar, 

Specialist in lung diseases, Paediatrician at NZOZ Optima in Przemyśl, Poland

The author declares no conflict of interest.

For media and medical inquiries, please contact us at:

This email is not for patients; we will not reply to any of those requests.

Note: Treatment should be carried out only on the recommendation of a doctor (the drug is on prescription), and the treatment itself is combined with symptomatic treatment and diet restrictions. CANNOT BE USED BY A PATIENT WITHOUT CONSTANT CONTACT WITH A DOCTOR!


  1. Amantadine as a drug to mitigate the effects of COVID-19
  2. Amantadine Treatment for People with COVID-19
  3. SARS-CoV-2 results in the Podkarpackie Province:

Additional note: If you intend to publish this article on other sites, please always include the link to the original to ensure continuity for future updates.

In Polish + comments section (also treated patients stories):

Image: CDC/ Alissa Eckert, MS; Dan Higgins, MAM –

Włodzimierz Bodnar
Specialist in lung diseases, Paediatrician at NZOZ Optima in Przemyśl, Poland

Polish version with comments section:

Komentarze (208)

Dodaj komentarz
  1. 10 maja 2021, 14:09
  2. 9 maja 2021, 17:52
  3. 9 maja 2021, 13:43
    An immunocompetent 169-day prolonged SARS-CoV-2 shedding patient with high neutralizing antibody
  4. 8 maja 2021, 21:45
    The COVID‐19 Menace SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines
  5. 8 maja 2021, 18:20
  6. 8 maja 2021, 5:49
    Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
  7. 8 maja 2021, 5:41
    Obstructive sleep apnea is highly prevalent in COVID19 moderate to severe ARDS survivors: Findings of level I Polysomnography in a tertiary care hospital
  8. 8 maja 2021, 5:34
    Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses
  9. 8 maja 2021, 5:32
    COVID-19 Dysautonomia
  10. 7 maja 2021, 17:44
    The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity
  11. 6 maja 2021, 20:00
    Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study
  12. 6 maja 2021, 19:55
    Researchers Tie Severe Immunosuppression to Chronic COVID-19 and Virus Variants
  13. 6 maja 2021, 14:20
    Free SARS-CoV-2 Spike Protein S1 Particles May Play a Role in the Pathogenesis of COVID-19 Infection
  14. 4 maja 2021, 20:37
  15. 4 maja 2021, 15:39
    GP73 is a glucogenic hormone regulating SARS-CoV-2-induced hyperglycemia
  16. 4 maja 2021, 14:59
    SARS-CoV-2 spike protein induces brain pericyte immunoreactivity in absence of productive viral infection
  17. 2 maja 2021, 6:17
  18. 1 maja 2021, 14:41
  19. 1 maja 2021, 7:28
  20. 1 maja 2021, 7:15
  21. 30 kwietnia 2021, 17:19
    Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes
  22. 30 kwietnia 2021, 12:04
    A molecular single-cell lung atlas of lethal COVID-19
  23. 30 kwietnia 2021, 9:26
  24. 30 kwietnia 2021, 9:15
  25. 28 kwietnia 2021, 14:45
    COVID-19-associated coagulopathy and antithrombotic agents—lessons after 1 year
  26. 26 kwietnia 2021, 18:15
    SARS-CoV-2 requires cholesterol for viral entry and pathological syncytia formation The SARS-CoV-2 RNA interactome
  27. 26 kwietnia 2021, 14:26
    A systematic review on Multisystem Inflammatory Syndrome in Children (MIS-C) with COVID-19: Development of a scoring system for clinical diagnosis
  28. 25 kwietnia 2021, 12:21
    Elevated biomarker for blood vessel damage found in all children with SARS-CoV-2
  29. 25 kwietnia 2021, 6:36
    COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system
  30. 24 kwietnia 2021, 20:22
    SARS-CoV-2 spike protein dictates syncytium-mediated lymphocyte elimination
  31. 24 kwietnia 2021, 12:41
    Peter McCullough, MD testifies How Successful Early Treatment for COVID Makes Vaccines Unnecessary
  32. 23 kwietnia 2021, 13:24
    !!!!! !!!!! !!!!! !!!!! !!!!!! !!!!! ! !!!! ! ! ! ! !!!!!!!!!!!!!!!!!!!! SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines
  33. 20 kwietnia 2021, 19:43
    Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19
  34. 20 kwietnia 2021, 14:05
    Molecular relationships between SARS-CoV-2 Spike protein and LIFR, a pneumonia protective IL-6 family cytokine
  35. 17 kwietnia 2021, 14:42
  36. 14 kwietnia 2021, 16:51
    !!!!!!! !!!!!! !!!!!!! !!!!!!!! !!!!!!!!!
  37. 14 kwietnia 2021, 14:16
  38. 14 kwietnia 2021, 13:47
    Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2
  39. 13 kwietnia 2021, 17:47
    Increased serum thromboxane A2 and prostacyclin but lower complement C3 and C4 levels in COVID-19: associations with chest CT-scan anomalies and lowered peripheral oxygen saturation.
  40. 13 kwietnia 2021, 15:14
  41. 12 kwietnia 2021, 18:01
    Multilevel proteomics reveals host perturbations by SARS-CoV-2 and SARS-CoV
  42. 11 kwietnia 2021, 10:23
    Early Ambulatory Multidrug Therapy Reduces Hospitalization and Death in High-Risk Patients with SARS-CoV-2 (COVID-19)
  43. 10 kwietnia 2021, 13:35
  44. 10 kwietnia 2021, 13:25
  45. 9 kwietnia 2021, 13:31
    A Comparison of Thrombosis and Hemorrhage Rates in Patients With Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation
  46. 7 kwietnia 2021, 23:57
    Not only ACE2—the quest for additional host cell mediators of SARS-CoV-2 infection: Neuropilin-1 (NRP1) as a novel SARS-CoV-2 host cell entry mediator implicated in COVID-19
  47. 7 kwietnia 2021, 23:47
    Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19
  48. 7 kwietnia 2021, 20:39
  49. 7 kwietnia 2021, 18:32
    Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia
  50. 7 kwietnia 2021, 15:46
    Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19
  51. 7 kwietnia 2021, 7:22
    Natural mucosal barriers and COVID-19 in children
  52. 5 kwietnia 2021, 15:13
    Clinical Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients
  53. 4 kwietnia 2021, 8:44
  54. 1 kwietnia 2021, 21:05
    Systems serology detects functionally distinct coronavirus antibody features in children and elderly
  55. 1 kwietnia 2021, 20:16
    Pathophysiology of SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience
  56. 1 kwietnia 2021, 13:37
  57. 31 marca 2021, 15:16
  58. 29 marca 2021, 19:40
  59. 27 marca 2021, 21:14
    SARS-CoV-2 and mitochondrial health: implications of lifestyle and ageing
  60. 27 marca 2021, 13:06
    Aberrant glycosylation of anti-SARS-CoV-2 IgG is a pro-thrombotic stimulus for platelets
  61. 26 marca 2021, 18:43
  62. 26 marca 2021, 18:38
  63. 24 marca 2021, 16:34
  64. 23 marca 2021, 15:28
    Human rhinovirus infection blocks SARS-CoV-2 replication within the respiratory epithelium: implications for COVID-19 epidemiology
  65. 22 marca 2021, 17:45
    Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia
  66. 22 marca 2021, 15:58
    Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study
  67. 21 marca 2021, 17:09
    SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies
  68. 18 marca 2021, 19:32
    COVID-19 hospitalization rates rise exponentially with age, inversely proportional to thymic T-cell production
  69. 18 marca 2021, 16:54
    Potential association of mast cells with coronavirus disease 2019
  70. 14 marca 2021, 10:52
    Comparison of clinical characteristics and disease outcome of COVID-19 and seasonal influenza
  71. 11 marca 2021, 17:08
  72. 5 marca 2021, 18:29
    Zachorowalem 15 lutego na covid19 moje objawy wysoka goczka 39.6 przez kilka dni bol w calym ciselera stracilem glos wypowiadajac pare slow szeptem bylo dla mnie wyzwaniem 23/2 test wykazal pozytywny Ja mieszkam w szwecji lekarze z ktorymi Miata kontakt moja Zona polecali mi lezenie I dmuchanie przez slomke w butelke z woda trenowac ploca i to tylko tyle Po znajomosciach otrzymalem recepte na amantadine w miedzy czasie uzywalem pARACETAMOL NA ZBICIECIE tmp.1/3 dostalem w koncu amantadine po uzyciu 100mg / 1 ampulla po 10 godzinach poczulem dosyc dobrze moj organizm zareagowal dobrze jestem Juz po 5 amp wrk I’ll kolor skory Paznokci moglem Wejsc na schody w domu niestety jeszcze jestem slaby no dostaje ataku kaszlu ale czuje poprawe o 50% jestem pelen nadzieji ze szybko stane na nogi mnie the kuracja pomaga Jak mowia tonacy brzytwy sie chwyta mialem pewne obawy ale Sam widze ze to dziala szkoda ze tak pozno to dostalem niestety w szwecji maja w magazynach I trzeba czekac na zrealizowanie zamowienia.Nawet nie moge podzielic sie ta informacja z Szwedzki mi lekarzami bo oni nawet Niewiedza co to jest za lekarstwo to na razie poczekamy jeszcze pare dni po braniu amantadine/Szwedzki nazwa Dinetrel 100 mg amantadin.hydrochlorid
  73. 23 lutego 2021, 19:25
  74. 21 lutego 2021, 18:04
    Coinfection with influenza A virus enhances SARS-CoV-2 infectivity
  75. 19 lutego 2021, 20:10
  76. 7 lutego 2021, 20:49
    A B C D
  77. 7 lutego 2021, 8:53
  78. 5 lutego 2021, 23:54
  79. 2 lutego 2021, 20:44
  80. 31 stycznia 2021, 10:16
    18F-FDG brain PET hypometabolism in patients with long COVID
  81. 29 stycznia 2021, 18:26
    mmune response to SARS-CoV-2 in the nasal mucosa in children and adults
  82. 26 stycznia 2021, 19:35
  83. 25 stycznia 2021, 21:36
    Immunobiology: The Immune System in Health and Disease. 5th edition.
  84. 24 stycznia 2021, 17:49
    Do an Altered Gut Microbiota and an Associated Leaky Gut Affect COVID-19 Severity?
  85. 23 stycznia 2021, 18:44
    Allergic Reactions Including Anaphylaxis
  86. 22 stycznia 2021, 20:11
  87. 22 stycznia 2021, 19:52
  88. 22 stycznia 2021, 19:51
  89. 22 stycznia 2021, 17:09
    Early induction of functional SARS-CoV-2 specific T cells .......
  90. 17 stycznia 2021, 19:40
  91. 16 stycznia 2021, 15:40
  92. 14 stycznia 2021, 16:08
    Positive association between COVID-19 deaths and influenza vaccination rates in elderly people worldwide
  93. 14 stycznia 2021, 15:46
  94. 13 stycznia 2021, 20:24
    Three reasons why COVID-19 can cause silent hypoxia
  95. 11 stycznia 2021, 17:37
  96. 10 stycznia 2021, 11:14
    Influenza Update: Seasonal and H1N1 Vaccines (Inactivating the neuraminidase part prevents further morbidity and mortality, and targeting the M2 protein part of the virus offers the potential for universal influenza vaccine production if the M2 protein's amino acid sequence remains unchanged.10,11 )
  97. 9 stycznia 2021, 14:23
  98. 8 stycznia 2021, 10:28
  99. 6 stycznia 2021, 15:41
    Antithrombotic Therapy in COVID-19
  100. 6 stycznia 2021, 13:31 co Pan Doktor sadzi na ten temat?
  101. 5 stycznia 2021, 21:36
    Autoimmune anti-DNA antibodies predict disease severity in COVID-19 patients
  102. 5 stycznia 2021, 10:33
  103. 4 stycznia 2021, 23:30,38403.html
  104. 4 stycznia 2021, 22:58
    Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: an in silico approach
  105. 4 stycznia 2021, 22:41
    Can melatonin reduce the severity of COVID-19 pandemic?
  106. 4 stycznia 2021, 17:52
    COVID-19: Significance of antibodies
  107. 4 stycznia 2021, 14:37
  108. 4 stycznia 2021, 11:59
  109. 3 stycznia 2021, 20:26
  110. 3 stycznia 2021, 10:24
    amantadine SARS ..... PD
  111. 2 stycznia 2021, 16:24
    Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs
  112. 2 stycznia 2021, 1:21
    Sufficient niacin supply: the missing puzzle piece to COVID-19, and beyond?
  113. 1 stycznia 2021, 21:52
  114. 1 stycznia 2021, 15:47
    SARS-CoV-2 RNA reverse-transcribed and integrated into the human genome
  115. 1 stycznia 2021, 15:31
  116. 31 grudnia 2020, 23:48
  117. 29 grudnia 2020, 17:41
  118. 29 grudnia 2020, 17:38
  119. 29 grudnia 2020, 15:19
    Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus
  120. 29 grudnia 2020, 10:04
  121. 29 grudnia 2020, 9:59
    Why is COVID-19 less severe in children?
  122. 28 grudnia 2020, 23:24
  123. 28 grudnia 2020, 19:34
  124. 27 grudnia 2020, 18:19
  125. 26 grudnia 2020, 19:31
  126. 25 grudnia 2020, 19:23
  127. 24 grudnia 2020, 23:07
  128. 24 grudnia 2020, 14:20
  129. 24 grudnia 2020, 12:35
  130. 24 grudnia 2020, 10:31
    GRYPA 1970
  131. 23 grudnia 2020, 16:31
  132. 22 grudnia 2020, 16:15
  133. 21 grudnia 2020, 20:03
  134. 19 grudnia 2020, 23:03
    drug in covid 19
  135. 19 grudnia 2020, 20:20
    SARS-CoV-2 Spike mutations
  136. 17 grudnia 2020, 23:56
  137. 17 grudnia 2020, 23:27
  138. 17 grudnia 2020, 18:08
    Exposure to Renin-Angiotensin System
  139. 17 grudnia 2020, 17:09
    UK GOV
  140. 17 grudnia 2020, 17:03
  141. 17 grudnia 2020, 14:55
  142. 17 grudnia 2020, 12:05
    Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion
  143. 17 grudnia 2020, 12:02
    Danske forskeres inhalationsbehandling af Covid-19 består test i dyr
  144. 16 grudnia 2020, 15:41
    Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome
  145. 16 grudnia 2020, 10:46
  146. 15 grudnia 2020, 14:28
    do przeczytania publikacja,drugi-typ-enzymu-konwertujacego-angiotensyne-mozliwa-rola-w-nadcisnieniu-tetniczym-i-chorobach
  147. 15 grudnia 2020, 0:52
    SPARK Drug Repurposing Conference Tel Aviv University Oct 2020
  148. 14 grudnia 2020, 13:59
    Бромгексин И Спиронолактон для лечения КоронаВирусной Инфекции,
  149. 12 grudnia 2020, 12:05
  150. 7 grudnia 2020, 19:27
  151. 6 grudnia 2020, 17:06
  152. 6 grudnia 2020, 14:39
  153. 6 grudnia 2020, 13:33
    do posłuchania
  154. 4 grudnia 2020, 23:22
  155. 4 grudnia 2020, 22:27
  156. 4 grudnia 2020, 22:18
  157. 3 grudnia 2020, 20:25
    Синтез производных адамантана.
  158. 1 grudnia 2020, 21:42
  159. 30 listopada 2020, 15:58
    Very great рost. I just stumbled upon your weblog and wantеԁ to mention that I have really lⲟved Ƅгowsing your weblog posts. After all I will be subscribing on your rѕs feed and I ɑm hoping you write agaіn very soon!
  160. 29 listopada 2020, 19:30
    SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology
  161. 29 listopada 2020, 19:28
  162. 28 listopada 2020, 13:34
    Glycyrrhizin: An alternative drug for the treatment of COVID-19 infection and the associated respiratory syndrome?
  163. 27 listopada 2020, 11:46
    I do agree with all of the ideas you have presented in your post. Theyre really convincing and will definitely work. Still, the posts are very short for beginners. Could you please extend them a bit from next time? Thanks for the post.
  164. 26 listopada 2020, 21:27
    Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
  165. 25 listopada 2020, 21:03
    SARS 2004 Inhibition of SARS Coronavirus Infection In Vitro with Clinically Approved Antiviral Drugs
    • 25 listopada 2020, 21:03
  166. 25 listopada 2020, 19:05
    NMDA Inhibitors
  167. 24 listopada 2020, 15:39
  168. 23 listopada 2020, 16:45
    bromhexine for the prevention and management of SARS-CoV-2 infection
  169. 23 listopada 2020, 16:26
    Possibility for the use of bromhexine to prevent infection with SARS-CoV-2
  170. 22 listopada 2020, 16:09
    po PL,profilaktyka-i-leczenie-grypy-w-sezonie-zachorowan?page=2
  171. 22 listopada 2020, 11:27
    Sars covv 2
  172. 21 listopada 2020, 9:59
    Coronavirus (COVID-19) .....
  173. 20 listopada 2020, 20:08
    SARS-CoV-2 , COVID , Natural deletions ....
  174. 18 listopada 2020, 20:17
    Amantadine: an antiviral and antiparkinsonian agent
  175. 18 listopada 2020, 18:36
    STAT2 signaling restricts viral dissemination but drives severe pneumonia in SARS-CoV-2 infected hamsters Central and peripheral nervous system complications of COVID-19: A prospective tertiary center cohort with 3-month follow-up
  176. 18 listopada 2020, 17:37
    The genetic structure of SARS‐CoV‐2 does not rule out a laboratory origin A continuously self-sterilizing form of copper capable of 99% SARS-CoV-2 deactivation in 30 seconds.
  177. 17 listopada 2020, 21:45
    Influenza and COVID-19
  178. 17 listopada 2020, 19:33
    Superiority of cilostazol among antiplatelet FDA‐approved drugs against COVID 19 Mpro and spike protein: Drug repurposing approach Discovery of rhodomyrtone as a broad-spectrum antiviral inhibitor with anti-SARS-CoV-2 activity Intra-host evolution during SARS-CoV-2 persistent infection Interferon-b trial shows positive results Role of air temperature and humidity in the transmission of SARS-CoV-2 in the United States
  179. 17 listopada 2020, 16:48
    JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality
  180. 16 listopada 2020, 16:34
    Rheumatoid arthritis drug shows promise against COVID-19, study finds
  181. 16 listopada 2020, 16:33
    Amantadine effective in COVID-19 ?
  182. 16 listopada 2020, 16:26
    Researchers identify promising new compounds to potentially treat novel coronaviruses
  183. 16 listopada 2020, 15:25
    Baricitinib treatment linked to reduced mortality in COVID-19 patients
  184. 15 listopada 2020, 21:57
    Szanowny Panie Doktorze. Czy można uzyskać informacje jakie dawki Pan stosował u pacjentow. Dziękuję. Tomasz
  185. 15 listopada 2020, 19:56
  186. 15 listopada 2020, 19:44
    Potential Effects of Coronaviruses on the Cardiovascular System
  187. 15 listopada 2020, 18:02
    Antiviral effects of nisin, lysozyme, lactoferrin and their mixtures against bovine viral diarrhoea virus
  188. 15 listopada 2020, 17:15
    A natural food preservative peptide nisin can interact with the SARS-CoV-2 spike protein receptor human ACE2
  189. 15 listopada 2020, 12:13
    Amantadine disrupts lysosomal gene expression; potential therapy for COVID19”
  190. 13 listopada 2020, 11:12
    Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
  191. 13 listopada 2020, 11:00
    Volunteers who received the Pfizer coronavirus vaccine have said it left them with side effects that felt similar to a “severe hangover,”
  192. 13 listopada 2020, 10:15
    Functional and druggability analysis of the SARS-CoV-2 proteome
  193. 13 listopada 2020, 10:08
    Structure and drug binding of the SARS-CoV-2
  194. 13 listopada 2020, 10:06
    Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication
  195. 12 listopada 2020, 14:14
    SARS-CoV-2 vaccines in development
  196. 12 listopada 2020, 11:00
    było na wykopie
  197. 11 listopada 2020, 13:35
    Fajnie się czyta, z racji że Covid mnie zamknął w mieszkaniu będę wpadać częściej
  198. 9 listopada 2020, 5:43
    Gwiazdor to człowiek, który latami pracuje jak opętany, by zyskać popularność, a potem zakłada polaryzacyjne okulary, żeby go nie rozpoznano... :-).
  199. 8 listopada 2020, 20:13
  200. 7 listopada 2020, 15:30
    to było w kwietniu
  201. 6 listopada 2020, 21:51
    Uprzejmie proszę o uaktualnienie strony, myślę że te informacje warto rozpowszechniać też za granicą.
    • 6 listopada 2020, 22:05
      Pracujemy nad tym, powinna się pojawić jutro.
  202. 6 listopada 2020, 20:51
    Amantadine for influenza A
  203. 2 listopada 2020, 15:42
    Bardzo dziękuję Panu Doktorowi za podpowiedz jak leczyć chorych w domu. Moja uwaga- jak najszybciej , przy najmniejszych pierwszych objawach podawać !!! Wirus uszkadza również osrodek oddechowy- w pewnym momencie mąz miał 6 oddechow na minutę, saturacja 80 - po ząłożeniu CPAP, bez tlenu- saturacja wróciła na 95%, i tak kilka razy- bez maski 80-87 max, z maską 95 i wyżej bez tlenu - Jutro dam ef....... , może prawidłowo ruszy tor oddychowy Ma nadkazenie bakteryjne/ niestety po Levoxie z V. zaczynają się drżenia grubofalowe mięsni ale jestesmy juz na 2 x 1 tabl więc uwaga na interakcje !!! Pozdrawiam wszystkich Ukłony dla Pana Doktora.
  204. 31 października 2020, 19:45
    Panie doktorze, prosze sie nie poddawac. Wiemy, ze cenzuruja wszystko co nie jest zgodne z wytycznymi.
  205. 31 października 2020, 1:12
    Kto Pana nastraszył?
    • 15 grudnia 2020, 17:40
      Widac, ze lobby farmaceutyczne ma swoje macki wszedzie.